|1.||Oerther, S: 2 articles (07/2001 - 12/2000)|
|2.||Miyoshi, Satoshi: 1 article (04/2014)|
|3.||Tatara, Ayaka: 1 article (04/2014)|
|4.||Sugiuchi, Tomone: 1 article (04/2014)|
|5.||Shimizu, Saki: 1 article (04/2014)|
|6.||Kizu, Tomoya: 1 article (04/2014)|
|7.||Ohno, Yukihiro: 1 article (04/2014)|
|8.||Sato, Maho: 1 article (04/2014)|
|9.||Andatsu, Saki: 1 article (04/2014)|
|10.||Leggio, Gian Marco: 1 article (03/2012)|
06/01/2000 - "Furthermore, it did not affect hypophagia or yawns, but attenuated hypothermia and PEs, elicited by 7-OH-DPAT. "
07/01/2001 - "As expected, 7-OH-DPAT [0.5 and 2.0 micromol x kg(-1) subcutaneous (s.c.)] as well as 8-OH-DPAT (0.15-2.4 micromol x kg(-1) s.c.), produced a dose-dependent hypothermia. "
09/01/1999 - "In order to investigate whether the DA D2 receptor is the subtype that mediates hypothermia and hypolocomotion produced by DA D2/D3 receptor agonists, we tested the effects of ip administration of the DA D2/D3 receptor agonists 7-OH-DPAT and PD 128907, on core temperature and locomotor activity in DA D2 receptor knock-out mice (homozygotes: D2(-/-) and heterozygotes: D2(+/-)), and in wild-type (D2(+/+)) mice. "
01/19/1998 - "The dose-dependent hypothermia produced by 7-OH-DPAT (0.06-1.00 micromol kg-1 s.c.) was also augmented in an additive manner by pretreatment with A 68930 (0.9 micromol kg-1 s.c.). "
12/18/2000 - "The results suggest that the hypothermia produced by the respective DA D2/3 and the 5-HT1A receptor agonists 7-OH-DPAT and 8-OH-DPAT is an active process, in all probability due to changes in a hypothalamic set-point for temperature regulation."
12/01/2002 - "In non-pigmented rabbits, the ocular hypotension induced by topical administration of 7-OH-DPAT (75 microg) with CAP (115 microg) was more pronounced and sustained than that of 7-OH-DPAT without CAP. "
03/01/2012 - "Pretreatment with U-99194A, a D₃ receptor antagonist, reverted 7-OH-DPAT induced ocular hypotension in WT mice. "
06/01/2000 - "Suppression of 7-OH-DPAT-induced ocular hypotension by D(3) receptor antagonists (U-99194A and UH232) and sympathectomy, coupled with the immunohistochemical data, suggested that the primary site of D(3) receptor-mediated action of 7-OH-DPAT is located on postganglionic sympathetic nerve endings in the ciliary body of rabbit."
11/26/1999 - "We further assessed the roles of the mesostriatal dopaminergic system and found that local perfusion of quinpirole and 7-OH-DPAT into the substantia nigra (SN) significantly aggravated cataplexy, while perfusion of a D2/D3 antagonist significantly reduced cataplexy. "
09/29/1999 - "We further assessed the roles of the mesostriatal dopaminergic system and found that local perfusion of quinpirole and 7-OH-DPAT into the substantia nigra (SN) significantly aggravated cataplexy, while perfusion of a D2/D3 antagonist significantly reduced cataplexy. "
09/09/1996 - "Local perfusion with the monoaminergic agonist quinpirole, 7-OH-DPAT and BHT-920, into the ventral tegmental area produced a dose-dependent increase in cataplexy without significantly reducing basal muscle tone. "
09/09/1996 - "Local perfusion with quinpirole, 7-OH-DPAT and BHT-920 into the globus pallidus/putamen also produced an increase, while raclopride produced a decrease, in cataplexy in narcoleptic canines. "
|3.||Dopamine D3 Receptors
|6.||5-HT1A Serotonin Receptor
|9.||3,4,4a,10b- tetrahydro- 4- propyl- 2H,5H- (1)benzopyrano(4,3- b)- 1,4- oxazin- 9- ol